These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 8806188

  • 1. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C, Mohn-Staudner A, Vetter H, Kokron O, Baumgartner G, Scheiner W, Zwick H, Koderhold G, Alth G, Dudczak R.
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [Abstract] [Full Text] [Related]

  • 2. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 3. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, Bombardieri E.
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [Abstract] [Full Text] [Related]

  • 4. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N.
    Anticancer Res; 2003 Mar; 23(2A):885-93. PubMed ID: 12820318
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S.
    Cancer; 1996 Apr 01; 77(7):1274-7. PubMed ID: 8608502
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T.
    Anticancer Res; 2001 Apr 01; 21(4B):3085-92. PubMed ID: 11712815
    [Abstract] [Full Text] [Related]

  • 9. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM, Sauer-Eppel H, Bruzdziak TH.
    Anticancer Res; 2007 Apr 01; 27(4A):1911-5. PubMed ID: 17649794
    [Abstract] [Full Text] [Related]

  • 10. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E.
    Anticancer Res; 1999 Apr 01; 19(4C):3613-8. PubMed ID: 10629660
    [Abstract] [Full Text] [Related]

  • 11. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM.
    Anticancer Res; 2005 Apr 01; 25(3A):1773-8. PubMed ID: 16033098
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Tumor markers in lung cancer].
    Niho S, Shinkai T.
    Gan To Kagaku Ryoho; 2001 Dec 01; 28(13):2089-93. PubMed ID: 11791391
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
    Koga H, Eguchi K, Shinkai T, Tamura T, Ohe Y, Oshita F, Saijo N, Kondo H, Oki K, Okura H.
    Jpn J Clin Oncol; 1994 Oct 01; 24(5):263-8. PubMed ID: 7526016
    [Abstract] [Full Text] [Related]

  • 17. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
    Pavićević R, Bubanović G, Franjević A, Stancić-Rokotov D, Samarzija M.
    Coll Antropol; 2008 Jun 01; 32(2):485-98. PubMed ID: 18756899
    [Abstract] [Full Text] [Related]

  • 18. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
    Oremek GM, Seiffert UB, Siekmeier R, Kirsten R.
    Med Klin (Munich); 1995 Jan 15; 90(1):23-6. PubMed ID: 7533887
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A, Soresi E, Boffi R, Nonis A, Noseda A, Cobelli S, Scanni A.
    Cancer Detect Prev; 1994 Jan 15; 18(3):209-20. PubMed ID: 8076383
    [Abstract] [Full Text] [Related]

  • 20. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F, Li WM, Wang DM, Gao SS, Bao Y, Chen WB, Liu D.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep 15; 39(5):832-5. PubMed ID: 19024326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.